Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Alemtuzumab

    Client Email Product

    Alemtuzumab

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    GLOBAL SALES INFORMATION

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    3
    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    3
    API REF. PRICE (USD / KG)

    0

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    3
    Europe

    Europe

    1
    Canada

    Canada

    2
    Australia

    Australia

    4
    South Africa

    South Africa

    3
    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    31.00

    Annual Reports

    454.00

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    34
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Genzyme`s Biologic Campath (alemtuzumab) Receives Approval in the U.S.
    Genzyme`s Biologic Campath (alemtuzumab) Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    08 Feb 2024
    Share Share
    Stem cell transplants may slow disability progression in MS
    Stem cell transplants may slow disability progression in MS

    https://www.europeanpharmaceuticalreview.com/news/177879/stem-cell-transplants-may-slow-disability-progression-in-ms/

    Caroline Peachey EUROPEANPHARMACEUTICALREVIEW
    22 Dec 2022
    Share Share
    Genzyme's Biologic Campath (Alemtuzumab) Receives Approval in the U.S.
    Genzyme's Biologic Campath (Alemtuzumab) Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    27 Sep 2022
    Share Share
    Genzyme's Lemtrada (alemtuzumab) Receives Approval in the U.S.
    Genzyme's Lemtrada (alemtuzumab) Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    26 May 2022
    Share Share
    Genzyme's Biologic Campath (Alemtuzumab) Receives Approval in the U.S.
    Genzyme's Biologic Campath (Alemtuzumab) Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    13 Jan 2022
    Share Share
    Genzyme's Biologic Lemtrada (Alemtuzumab) Receives Approval in the U.S.
    Genzyme's Biologic Lemtrada (Alemtuzumab) Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    13 Jan 2022
    Share Share
    Genzyme's Biological Alemtuzumab Receives Approval In the US
    Genzyme's Biological Alemtuzumab Receives Approval In the US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    20 Aug 2021
    Share Share
    Genzyme`s Lemtrada (Alemtuzumab) Receives Supplimental Approval in US
    Genzyme`s Lemtrada (Alemtuzumab) Receives Supplimental Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    27 Oct 2020
    Share Share
    Genzyme`s Campath (Alemtuzumab) Receives Supplimental Approval in US
    Genzyme`s Campath (Alemtuzumab) Receives Supplimental Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    27 Oct 2020
    Share Share
    MabCampath (alemtuzumab) - Risk of Haemophagocytic Lymphohistiocytosis, Stroke
    MabCampath (alemtuzumab) - Risk of Haemophagocytic Lymphohistiocytosis, Stroke

    https://www.firstwordpharma.com/node/1734789

    FIRSTWORDPHARMA
    22 Jun 2020
    Share Share
    Sanofi to pay nearly $12 million for illegally using a charity to pay kickbacks to Medicare patients
    Sanofi to pay nearly $12 million for illegally using a charity to pay kickbacks to Medicare patients

    https://www.justice.gov/usao-ma/pr/sanofi-agrees-pay-1185-million-resolve-allegations-it-paid-kickbacks-through-co-pay

    DOJ
    03 Mar 2020
    Share Share
    Lemtrada (alemtuzumab): updated restrictions and strengthened monitoring
    Lemtrada (alemtuzumab): updated restrictions and strengthened monitoring

    https://www.gov.uk/drug-safety-update/lemtrada-alemtuzumab-updated-restrictions-and-strengthened-monitoring-requirements-following-review-of-serious-cardiovascular-and-immune-mediated-reactions

    GOVUK
    13 Feb 2020
    Share Share
    Genzyme's LEMTRADA (Alemtuzumab) Receives Supplimental Approval in U.S
    Genzyme's LEMTRADA (Alemtuzumab) Receives Supplimental Approval in U.S

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    27 Nov 2019
    Share Share
    Genzyme's CAMPATH (Alemtuzumab) Receives Supplimental Approval in U.S
    Genzyme's CAMPATH (Alemtuzumab) Receives Supplimental Approval in U.S

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    27 Nov 2019
    Share Share
    Sanofi settles Lemtrada dispute with Genzyme investors for $315m
    Sanofi settles Lemtrada dispute with Genzyme investors for $315m

    http://www.pmlive.com/pharma_news/sanofi_settles_lemtrada_dispute_with_genzyme_investors_for_$315m_1315185

    Phil Taylor PMLIVE
    04 Nov 2019
    Share Share
    PRAC cautions use of Lemtrada, Xeljanz in latest meeting
    PRAC cautions use of Lemtrada, Xeljanz in latest meeting

    http://www.pharmatimes.com/news/prac_cautions_use_of_lemtrada,_xeljanz_in_latest_meeting_1315052

    Anna Smith PHARMATIMES
    02 Nov 2019
    Share Share
    Genzyme’s Campath (Alemtuzumab) Receives Supplemental Approval In US
    Genzyme’s Campath (Alemtuzumab) Receives Supplemental Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    29 Oct 2019
    Share Share
    Genzyme’s Lemtrada (Alemtuzumab) Receives Supplemental Approval In US
    Genzyme’s Lemtrada (Alemtuzumab) Receives Supplemental Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    29 Oct 2019
    Share Share
    Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
    Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds

    https://www.biopharmadive.com/news/multiple-sclerosis-drug-costs-skyrocketed-for-medicare-and-patients-study/561757/

    Andrew Dunn BIOPHARMADIVE
    27 Aug 2019
    Share Share
    Genzyme’s Campath (Alemtuzumab) Receives Supplemental Approval In US
    Genzyme’s Campath (Alemtuzumab) Receives Supplemental Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    03 Aug 2019
    Share Share
    Maia Pharms Generic Baclofen Receives Approval in US
    Maia Pharms Generic Baclofen Receives Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210315

    FDA
    02 Aug 2019
    Share Share
    Lemtrada & serious cardiovascular and immune-mediated adverse reactions
    Lemtrada & serious cardiovascular and immune-mediated adverse reactions

    https://www.gov.uk/drug-safety-update/lemtrada-alemtuzumab-and-serious-cardiovascular-and-immune-mediated-adverse-reactions-new-restrictions-to-use-and-strengthened-monitoring-requirements

    MHRA
    17 May 2019
    Share Share
    Genzyme`s Campath (Alemtuzumab) Receives Approval in US
    Genzyme`s Campath (Alemtuzumab) Receives Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    25 Apr 2019
    Share Share
    Sanofi's Lemtrada goes under EU review for fatal side effects
    Sanofi's Lemtrada goes under EU review for fatal side effects

    https://www.fiercepharma.com/pharma/sanofi-s-lemtrada-under-review-eu-for-fatal-side-effects-heart-blood-vessels

    Kyle Blankenship FIERCE PHARMA
    16 Apr 2019
    Share Share
    The Warren bill could promote beneficial public-private partnerships in the life sciences
    The Warren bill could promote beneficial public-private partnerships in the life sciences

    https://www.statnews.com/2019/01/21/warren-bill-promote-public-private-partnerships/

    Su Linna STAT NEWS
    22 Jan 2019
    Share Share
    Genzyme's Campath (Alemtuzumab) Receives Approval in US
    Genzyme's Campath (Alemtuzumab) Receives Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    16 Jan 2019
    Share Share
    Bluebird’s anti-BCMA has a ‘clear lead’ in a crowded field
    Bluebird’s anti-BCMA has a ‘clear lead’ in a crowded field

    https://www.fiercebiotech.com/biotech/ash18-bluebird-s-anti-bcma-has-a-clear-lead-a-crowded-field

    Phil Taylor FIERCE BIOTECH
    06 Dec 2018
    Share Share
    Genzyme’s Biological Lemtrada (Alemtuzumab) Receives Supplemental Approval In US
    Genzyme’s Biological Lemtrada (Alemtuzumab) Receives Supplemental Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    03 Dec 2018
    Share Share
    FDA hits Sanofi's struggling Lemtrada with new safety warning over reports
    FDA hits Sanofi's struggling Lemtrada with new safety warning over reports

    https://www.fiercepharma.com/pharma/fda-hits-sanofi-s-struggling-lemtrada-new-safety-warning-over-reports-stroke-artery-tears

    Carly Helfand FIERCE PHARMA
    01 Dec 2018
    Share Share
    Genzyme's Biological Alemtuzumab Receives Approval in US
    Genzyme's Biological Alemtuzumab Receives Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    29 Nov 2018
    Share Share
    Can Sanofi's new long-term Lemtrada data amp up MS sales?
    Can Sanofi's new long-term Lemtrada data amp up MS sales?

    https://www.fiercepharma.com/pharma/can-sanofi-s-new-long-term-lemtrada-amp-up-sales-a-crowded-ms-field

    Carly Helfand FIERCE PHARMA
    12 Oct 2018
    Share Share
    Sanofi Presents 8-Year Data on Lemtrada® (Alemtuzumab)
    Sanofi Presents 8-Year Data on Lemtrada® (Alemtuzumab)

    https://www.businesswire.com/news/home/20181010005474/en/Sanofi-Presents-8-Year-Data-Lemtrada%C2%AE-Alemtuzumab

    BUSINESSWIRE
    10 Oct 2018
    Share Share
    Sanofi bets big on India
    Sanofi bets big on India

    https://www.manufacturingchemist.com/news/article_page/Sanofi_bets_big_on_India/146656

    MANUFACTURING CHEMIST
    29 Aug 2018
    Share Share
    Sanofi’s internal memo after a subpoena illustrates concerns over MS drug Mkg
    Sanofi’s internal memo after a subpoena illustrates concerns over MS drug Mkg

    https://www.statnews.com/pharmalot/2018/05/30/sanofi-subpoena-feds-charities/

    Ed Silverman STATNEWS
    30 May 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search